EAU 2013 - Programme Book - YouMed

Monday
Monday, 18 March - EAU Programme
312 Programme Book
Abstract Session
15.45 - 17.15 Pharmacotherapy of male LUTS
Blue Hall 1-2 - Level N1
Poster Session 89
Chairs: C.G. Roehrborn, Dallas (US)
M.J. Speakman, Taunton (GB)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
* 1085 Adverse event profiles of alpha-1 blocker agents for male patients: Data mining of the public version of the
FDA adverse event reporting system
K. Yoshimura, K. Kadoyama, T. Sakaeda, Y. Sugino, O. Ogawa, Y. Okuno (Kyoto, Japan)
1086 Acute urinary retention risk in BPH patients treated with tamsulosin vs watchful waiting: A 5 year
prospective community based study
K. Lokshin, M. Davidov, I. Gorbunova (Moscow, Perm, Russia)
1087 The Silodosin in Real-life Evaluation (SiRE) study: Baseline characteristics of the patients enrolled in a
European phase IV clinical study with silodosin in the treatment of LUTS/BPH
C.R. Chapple (Sheffield, United Kingdom)
1088 Urinary retention following anticholinergics in patients with BPH in real life practice - a nationwide
population-based study
E.Y-H. Huang, C-C. Lin, H.-. Chung, J-P. Lin, A.T. Lin, K-K. Chen (Taipei, Taiwan)
* 1089 Quality of life analyses from NEPTUNE, a phase 3 trial of combination therapy with tamsulosin OCAS and
solifenacin in men with lower urinary tract symptoms
M.J. Drake, R. Sokol, M. Klaver, T. Drogendijk, Z. Hakimi, I. Odeyemi, P.E.V. Van Kerrebroeck (Bristol,
Chertsey, United Kingdom; Trencin, Slovakia; Leiderdorp, Maastricht, The Netherlands)
1090 Predictors of successful first-line antimuscarinics monotherapy in men with enlarged prostate and
predominant storage symptoms
C.H. Liao, H.C. Kuo (New Taipei City, Hualien, Taiwan)
1091 Effects of add-on mirabegron on storage symptoms in men with lower urinary tract symptoms receiving
alpha-1 blocker therapy
K. Ogura, A. Sengiku, Y. Miyazaki, H. Sawazaki, T. Takahashi (Otsu, Japan)
1092 Combination therapy with dutasteride and tadalafil in men with moderate-to-severe benign prostatic
hyperplasia
H.J. Park, N.C. Park (Busan, South Korea)
1093 Clinical effects of dutasteride and finasteride: Are they different or equivalent? Results from record-linkage
and match-paired analyses
L. Cindolo, C. Fanizza, M. Romero, L. Pirozzi, R. Autorino, F. Berardinelli, L. Schips (Vasto-Chieti, Santa
Maria Imbaro-Chieti, Naples, Italy)
1094 Clinical outcomes after combined therapy with 5alpha-reductase inhibitors and alpha-blockers or either
monotherapy in men with benign prostatic hyperplasia: 4-year results from a record-linkage analysis
L. Cindolo, C. Fanizza, M. Romero, L. Pirozzi, R. Autorino, F. Berardinelli, C. De Nunzio, L. Schips (Vasto-
Chieti, Santa Maria Imbaro-Chieti, Naples, Rome, Italy)